China’s NeuCyber Matrix BMI Pioneers World First: High-Throughput Flexible Semi-Invasive Wireless BMI Implant in Humans
The “NeuCyber Matrix BMI System”, a wireless Brain-Machine Interface (BMI) system collaboratively developed by the Chinese Institute for Brain Research, Beijing (CIBR) and NeuCyber NeuroTech (Beijing) Co., Ltd., has entered its initial clinical investigation with a cohort of three human implantations, enabling paralyzed patients to achieve mind-controlled operation of computers and robotic arms, while a dysarthria patient to decode and output Chinese speech.
Designed for functional substitution and rehabilitation in patients with motor impairments caused by spinal cord injuries, strokes, or related conditions, or augmentative speech output for dysarthria patient, the System employs nano-fabrication technologies to develop thin, flexible, high-throughput μECoG electrodes. These electrodes achieve optimal contact with brain tissue, reducing impedance while significantly enhancing the signal-to-noise ratio and spatial resolution of neural recordings. As a 128-channel wireless long-term implantable semi-invasive BMI, the System delivers the highest signal throughput in its category.
Its performance stems not only from advanced electrodes but three additional innovations:
1. A miniaturized high-integration processor enabling large-scale neural signal processing with low power consumption.
2. Next-gen short-range wireless communication supporting high-throughput data transmission at ultra-low energy consumption.
3. High accuracy while low latency decoding and recoding algorithms adapted for various context, generating precise control commands for computers, smart devices, and other external devices such as rehabilitation equipment—enabling more natural motor control and high-accuracy Mandarin speech decoding.
The System has passed rigorous tests according to medical device standards and biological safety evaluations both in vitro and in vivo. Preclinical testing demonstrated adequate safety and stable performance after long-term implantation in animals. For example, the System can record and process ECoG signals for over 8 hours continuously.
Since the beginning of 2025, CIBR and NeuCyber NeuroTech are collaborating with Peking University First Hospital, Xuan Wu Hospital, and Beijing Tiantan Hospital to clinically validate the System. The first three human implantations have been achieved between February and March, including a paraplegic patient with spinal cord injury, an ALS patient with dysarthria, and a hemiplegic stroke survivor.
Clinical evidence demonstrates that over 98% of the channels remain functional post-surgery. Paralyzed patients are successfully adapting to and utilizing the system to control external devices, compensating for their loss of motor function. Notably, for the first time, a dysarthria patient has been able to output Chinese speech through the System, with projections to reach contextually fluent Mandarin output (80+ characters/minute) within three to six months—effectively regaining the ability to communicate.
Prior to the “NeuCyber Matrix BMI System” deployment, global high-throughput semi-invasive systems in human patients relied mainly on wired configurations, while wireless alternatives paled in channel capacity—none matching its 128-channel benchmark. For instance, a Switzerland’s research group using Clinatec WIMAGINE system required dual-device implantation to achieve just 64 channels for its pioneering trial enabling paralyzed patients to stand and walk. Moreover, unlike Neuralink’s Telepathy system—which employs penetrating microelectrodes that pierce brain tissue to record single-neuron signals—the NeuCyber Matrix BMI System’s flexible μECoG electrodes acquire cortical surface signals, eliminating risks associated with invasive brain penetration while maintaining clinical-grade spatial resolution.
The NeuCyber Matrix BMI System is advancing toward maturity as a medical product, with its technological breakthroughs demonstrating clear potential to benefit vast patient populations. The initial validation of its core functionalities—motor and speech decoding—has established a robust foundation for subsequent clinical translation and scaled production. Once the clinical translation is completed and large - scale application is achieved, the system is poised to transcend traditional healthcare resource limitations, delivering standardized, replicable solutions for global patients with paralysis or speech impairments while bridging the critical gap between lab research and clinical practice.
Beyond its current applications, the system’s technological boundaries are rapidly expanding:
1. Nervous system diseases: By integrating precise neural monitoring with stimulation capabilities, it holds promise in addressing Parkinson’s disease tremors and suppressing epileptic discharges.
2. Mental health: For depression and anxiety patients, its neurofeedback training enables real-time visualization of brain activity, empowering regulation of aberrant neural patterns to alleviate symptoms—a precision tool for psychiatric intervention.
3. Sensory restoration: The system is expected to explore neural signal modulation to restore vision, hearing, and other senses, alongside non-pharmacological approaches to chronic pain management.
The long-term vision centers on seamlessly connecting the human brain with the digital world, driving transformative shifts in healthcare delivery and human - machine interaction.
Collaborative Development Organizations
The NeuCyber Matrix BMI System was jointly developed through a collaborative effort between the Chinese Institute for Brain Research, Beijing (CIBR) and NeuCyber NeuroTech (Beijing) Co., Ltd.. Dr. Minmin Luo in CIBR serves as the Chief Scientist overseeing the overall technical roadmap. Core team members include Drs. Ting Wu, He Cui , YunZhe Liu, Lei Zhang, Jue Xie and Yuan Li. The first three human implantations were conducted in collaboration with Peking University First Hospital, Xuan Wu Hospital, and Beijing Tiantan Hospital.
Organization Overview
1. Chinese Institute for Brain Research, Beijing (CIBR)
The Chinese Institute for Brain Research, Beijing (CIBR) was established on March 22, 2018. It is one of the first new-type research institutions prioritized by People's Government of Beijing Municipality to advance the development of a national science and technology innovative hub and align with national major science and technology projects. CIBR operates as an independent legal entity jointly established by the Beijing Municipality, the Chinese Academy of Sciences, Peking University, Tsinghua University, Beijing Normal University, the Chinese Academy of Medical Sciences, and the China Academy of Chinese Medical Sciences. We focus on key research areas including the fundamental principles of the brain, brain disorders, neuroscience methods, and neural computation and neuroengineering.
2. NeuCyber NeuroTech (Beijing) Co. ,Ltd.
Established in March 2023, NeuCyber NeuroTech (Beijing) Co. ,Ltd. is designated to implement the "Intelligent BMI Enhancement Initiative." This initiative strategically advances cutting-edge implantable brain-machine interface (BMI) technologies—including electrodes and other core components as well as decoding algorithms, accelerating clinical product R&D and real-world application.
3. Peking University First Hospital
As China’s first state-founded national hospital, it ranks among the country’s top-tier and globally leading medical institutions. Its clinical medicine discipline is fully integrated into China’s "Double First-Class" initiative, cementing its role as a national hub for cutting-edge clinical research and translational innovation. The hospital was awarded "A++++" status in the 2023 China Hospital Comprehensive Competitiveness Rankings.
4. Xuanwu Hospital, Capital Medical University
A National Center for Neurological Disorders and China’s earliest adopter of BMI clinical applications, Xuanwu Hospital has pioneered multiple domestic and global "firsts" in neurological therapeutics. It has developed and refined BMI-based diagnostic and treatment systems for epilepsy, spinal cord injuries, and other conditions, establishing itself as a leader in neurotechnology innovation.
5. Beijing Tiantan Hospital, Capital Medical University
Serves as the national clinical research center for neurological diseases and the national center for neurological disorders, Tiantan Hospital launched China’s first hospital-led BMI Translational Research Center in 2022. The center drives clinical studies and industrial partnerships to advance brain-machine intelligent technologies.
FQA: NeuCyber Matrix BMI System
Q1: What is the NeuCyber Matrix BMI System?A: The NeuCyber Matrix BMI System comprises three core components:
· Implantable micro-device: Surgically placed in the skull with flexible electrodes positioned epidurally (outside the dura mater), avoiding brain tissue penetration. The scalp is fully sutured post-implantation, minimizing surgical risks.
· Wearable external module: A non-invasive arm-worn unit wirelessly powers the implant and enables data transmission.
· Software suite: Processes and decodes electrocorticography (ECoG) signals to enable brain-controlled external devices or speech output.
Q2: What are the system’s technical breakthroughs?A: Four key innovations drive its performance:
1. Flexible, high-density thin-film electrodes for precise neural signal acquisition.
2. Highly integrated micro-processor enabling 128-channel signal processing at ultra-low power.
3. Next-gen short-range wireless tech supporting high-bandwidth transmission with minimal energy consumption.
4. Multi-scenario decoding algorithms achieving low latency for real-time device control and Mandarin speech reconstruction.
Q3: How does it compare to other BMI products?
A: The NeuCyber Matrix delivers two landmark advancements:
1. First 128-channel wireless semi-invasive system: Doubles the channel count of Clinatec WIMAGINE (64 channels) while eliminating wired constraints seen in earlier clinical systems.
2. Non-penetrating safety: Unlike Neuralink’s penetrating electrodes that pierce brain tissue, its μECoG electrodes acquire cortical surface signals epidurally, eliminating risks of parenchymal damage.
Q4: What clinical milestones have been achieved?A: In February-March 2025, three pioneering implantations were completed (a paraplegic individual with spinal cord injury, an ALS patient with dysarthria, and a hemiplegic stroke survivor). Postoperative evaluations confirmed over 98% functional electrode channels across all cases.
The system enables patients with motor impairments to control computers, smart devices, and robotic arms via neural signals while integrating functional electrical stimulation (FES) for limb rehabilitation. Paralyzed patients are successfully adapting to and utilizing the system to control external devices, compensating for their loss of motor function.
Notably, for the first time, a dysarthria patient has been able to output Chinese language through the System, with projections to reach contextually fluent Mandarin output (80+ characters/minute) within three to six months—effectively regaining the ability to communicate.
Q5：How is safety ensured?A: Key safeguards include:
1. Biocompatible electrodes: Fabricated from high-biocompatibility flexible polymer, positioned epidurally (outside the dura mater) without direct brain tissue contact.
2. Fully sealed wireless micro-implant: Allows for complete scalp closure post-surgery—significantly reducing surgical risks, minimizing tissue damage, and eliminating transcutaneous infection risks associated with wired systems.
3. 98% post-op channel reliability: Clinical outcomes demonstrate excellent postoperative recovery. The exceptional signal retention rate confirms the implant's stability and neural recording reliability meet stringent clinical application standards.
Q6: What industries will benefit from its commercialization?A: The system will catalyze advancements in:
1. Biomaterials: High-throughput flexible electrodes.
2. AI: Adaptive neuro-decoding algorithms.
3. Precision manufacturing: Miniaturized implantable devices.
Notably, its electrode technology could redefine global BCI hardware standards.
Q7: What are its intended applications?A: The System is strictly dedicated to medical rehabilitation, prioritizing motor function restoration and speech communication recovery while explicitly excluding cognitive enhancement—a design philosophy aligned with global ethical guidelines for neurotechnology. Looking ahead, establishing robust neural data security protocols, particularly advanced encryption mechanisms for wireless signal transmission, will be critical to safeguarding patient privacy as the technology scales.
Q8: Is this technology limited to medical applications?
A: The development of this technology is exclusively focused on medical rehabilitation, specifically for conditions such as spinal cord injuries, stroke, and ALS, with the aim of significantly improving patients' quality of life. Its technical features—such as Mandarin-focused decoding and flexible electrodes—are designed to meet clinical needs. There are no current or planned military applications for this technology.
